CoChat

Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer’s disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs− it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + ( p < 0.001). This trend was driven by LOAD (Δ-MMSE:−10.8 vs. −5.7 points; p < 0.001), although a similar effect was observed in VD (Δ-MMSE:−11.6 vs. −8.8; p < 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53–0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-022-16476-w

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of the study.
Figure 1 Flow chart of the study.CC BY · PubMed Central
Figure 2 Mini Mental State Examination (MMSE) score during follow-up in all patients with dementia (A), LOAD (B), and vascular dementia (C) according to treatment with AChEIs. ***p < 0.001 for trend (Adjusted curves–for propensity score matched cohorts).
Figure 2 Mini Mental State Examination (MMSE) score during follow-up in all patients with dementia (A), LOAD (B), and vascular dementia (C) according to treatment with AChEIs. ***p < 0.001 for trend (Adjusted curves–for propensity score matched cohorts).CC BY · PubMed Central
Figure 3 Cumulative survival (Cox multivariate regression analysis) after propensity score matching in patients with dementia treated or not treated with AChEIs: (A) all patients; (B) LOAD; (C): vascular dementia.
Figure 3 Cumulative survival (Cox multivariate regression analysis) after propensity score matching in patients with dementia treated or not treated with AChEIs: (A) all patients; (B) LOAD; (C): vascular dementia.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 2

  1. Kumar A, Sharma S. Donepezil. [Updated 2020 Aug 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513257/
  2. Nelson PT Kryscio RJ Abner EL Schmitt FA Jicha GA Mendiondo MS Cooper G Smith CB Markesbery WR Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with alzheimer's disease and AD + DLB J Alzheimers Dis. 2009 16 1 29 34 10.3233/JAD-2009-0926 19158418 PMC2682919 · DOI · Paper page

Cited by

See all 72

Metadata

Authors
Zuin, M., Cherubini, A., Volpato, S., Ferrucci, L., & Zuliani, G.
Affiliations
  • University of Ferrara (IT)
  • Istituto Nazionale di Riposo e Cura per Anziani (IT)
  • National Institutes of Health (US)
Corresponding author
Zuliani, Giovanni
Venue
Scientific Reports
Published
2022-07-16
Volume
12
Issue
1
Pages
12214-12214
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4285588825
Cited by
72
References
38
Citations by year
2026: 20 · 2025: 20 · 2024: 19 · 2023: 13
FWCI
8.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion, cc-by)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, cc-by)
Funders
NIA/NIH (U01 AG016976)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
acetylcholinesterase inhibitors, dementia, cognitive decline, all-cause mortality, late-onset Alzheimer's disease, vascular dementia, Lewy body disease, older adults, Mini-Mental State Examination, real-world effectiveness
MeSH terms
Aged, Alzheimer Disease, Cholinesterase Inhibitors, Cholinesterases, Humans, Lewy Body Disease, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. https://app.cochat.ai/papers/10.1038/s41598-022-16476-w
The paper
Zuin, M., Cherubini, A., Volpato, S., Ferrucci, L., & Zuliani, G. (2022). Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. Scientific Reports. https://doi.org/10.1038/s41598-022-16476-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.